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Abstract
Background: Glyoxalase 1 is a key enzyme in the detoxification of reactive metabolites such as methylglyoxal and
induced Glyoxalase 1 expression has been demonstrated for several human malignancies. However, the regulation
and clinical relevance of Glyoxalase 1 in the context of head and neck squamous cell carcinoma has not been
addressed so far.
Methods: Argpyrimidine modification as a surrogate for methylglyoxal accumulation and Glyoxalase 1 expression in
tumor cells was assessed by immunohistochemical staining of tissue microarrays with specimens from oropharyngeal
squamous cell carcinoma patients (n = 154). Prognostic values of distinct Glyoxalase 1 staining patterns were
demonstrated by Kaplan-Meier, univariate and multivariate Cox proportional hazard model analysis. The impact of
exogenous methylglyoxal or a Glyoxalase 1 inhibitor on the viability of two established tumor cell lines was monitored
by a colony-forming assay in vitro.
Results: Glyoxalase 1 expression in tumor cells of oropharyngeal squamous cell carcinoma patients was positively
correlated with the presence of Argpyrimidine modification and administration of exogenous methylglyoxal induced
Glyoxalase 1 protein levels in FaDu and Cal27 cells in vitro. Cal27 cells with lower basal and methylglyoxal-induced
Glyoxalase 1 expression were more sensitive to the cytotoxic effect at high methylgyoxal concentrations and both cell
lines showed a decrease in colony formation with increasing amounts of a Glyoxalase 1 inhibitor. A high and nuclear
Glyoxalase 1 staining was significantly correlated with shorter progression-free and disease-specific survival, and served
as an independent risk factor for an unfavorable prognosis of oropharyngeal squamous cell carcinoma patients.
Conclusions: Induced Glyoxalase 1 expression is a common feature in the pathogenesis of oropharyngeal squamous
cell carcinoma and most likely represents an adaptive response to the accumulation of cytotoxic metabolites.
Oropharyngeal squamous cell carcinoma patients with a high and nuclear Glyoxalase 1 staining pattern have a high
risk for treatment failure, but might benefit from pharmacological targeting Glyoxalase 1 activity.
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Background
The Warburg effect describes a condition in which cells
with high proliferative activity rely on glycolysis as a
major source of energy rather than oxidative phosphor-
ylation [1]. High glycolytic activity is a characteristic fea-
ture of tumor cells in pre-malignant lesions as an
adaptation to intermitted hypoxia and is particularly
marked in invasive tumors [2]. As a consequence of ac-
celerated glycolysis cancer cells accumulate endogenous
dicarbonyl compounds such as methylglyoxal (MG), a
highly reactive and potent glycating agent [3]. Insuffi-
cient metabolism of MG causes stable modifications of
proteins, e.g. modification at arginine residues known as
argpyrimidine (AP), nucleotides and lipids, leading to ac-
celerated levels of advanced glycation end products
(AGEs). These modifications cause serious damage to the
functional integrity of the genome and the proteome [4].
The carbonyl stress related to MG has been primarily de-
scribed in the pathology of diabetes, where accumulation
of AGEs is a common event in the manifestation and
maintenance of late complications [5, 6]. MG is a potent
cytotoxic compound and its accumulation exerts anti-
tumor activity suggesting its potential use as therapeutic
agent in distinct cancers [7]. However, several studies also
reported a putative pro-tumorigenic effect of MG mainly
due to post-translational modification of cancer-related
proteins, indicating an impact of the global cellular
context.
In mammalian cells, MG is detoxified by the glyoxa-
lase system, an ubiquitous cellular defense mechanism
comprising glyoxalase 1 (GLO1), glyoxalase 2 (GLO2/
HAGH) and a catalytic amount of reduced glutathione
[3]. The glyoxalase system has been considered to main-
tain tumor cell activity and viability by preventing cellu-
lar suicide due to MG accumulation. Indeed, GLO1 gene
amplification and elevated expression is a common fea-
ture in the progression of multiple human malignancies,
including gastric cancer [8], colorectal cancer [9], breast
cancer [10], liver cancer [11, 12], skin tumors [13, 14],
and prostate cancer [15]. In some tumor entities GLO1
expression was associated with advanced tumor stages
or drug resistance [3, 8, 10, 16]. The increase in GLO1
expression and activity most likely resembles a strategy
adopted by aggressive cancer cells as a defense mechan-
ism against glycation damage induced by high intracellu-
lar MG levels as a consequence of elevated glycolytic
activity or under therapeutic conditions [3]. Thus, GLO1
plays a vital role in tumor initiation, malignant progres-
sion as well as treatment failure, and could serve as
promising target for anti-cancer therapy.
So far, neither the expression of GLO1 nor its impact
on malignant progression or prognosis have been ad-
dressed for head and neck squamous cell carcinoma
(HNSCC). HNSCC is one of the most common human
malignancies with an annual incidence of 600,000 new
cases worldwide [17]. Traditional risk factors are tobacco
and alcohol abuse and more recently, infection by high-
risk types of human papilloma virus (HPV), especially
HPV16, has been related to an escalating incidence of oro-
pharyngeal squamous cell carcinoma (OPSCC) [18, 19].
Despite aggressive and multimodal therapy mainly con-
sisting of surgery, radiotherapy and platinum-based
chemotherapy, the survival of patients with advanced
HNSCC has only marginally improved during the past de-
cades. Consequently, appropriate treatment of HNSCC
patients is still a major challenge and there is an urgent
demand for new concepts of more effective and less toxic
therapy.
Methods
Patient samples and tissue microarray
Tumor specimens for this retrospective study were ob-
tained from patients with primary OPSCC, who have
given informed consent to participate and were treated
at the University Hospital Heidelberg between 1990 and
2008. Formaldehyde fixed and paraffin embedded tissue
specimens were provided by the tissue bank of the Na-
tional Center for Tumor Disease (Institute of Pathology,
University Hospital Heidelberg) after approval by the
local institutional review board (ethic vote: 176/2002
and 206/2005). The study was performed according to
the ethical standards of the Declaration of Helsinki. For
all tumor samples, clinical and follow-up data were avail-
able from the Department of Otolaryngology, Head and
Neck Surgery at the University Hospital Heidelberg and
are listed in Additional file 1: Table S1. HPV16 DNA
and viral transcript status was determined previously
[20] and generation of tissue microarrays has been de-
scribed elsewhere [21].
Immunohistochemical staining and scoring system
Tissue microarrays were assembled with independent
cores from distinct areas of a formalin-fixed and paraffin
embedded pre-treatment tumor tissue and for most tu-
mors at least two independent probes were available.
Tissue microarrays were incubated with anti-AP or anti-
GLO1 antibodies that are listed in Additional file 2: Table
S2. Immunostaining was visualized with the TSA Amplifi-
cation Kit (Perkin Elmer, Rodgau, Germany) and DAB per-
oxidase substrate (Vector Laboratories, Burlingame, USA)
according to the manufacturers instructions. Counterstain-
ing was done by hematoxylin to visualize tissue integrity.
Stained tissue microarrays were scanned using the Nano-
zoomer HT Scan System (Hamamatsu Photonics, Japan).
Protein expression was evaluated by three independent ob-
servers using the NDP Viewer software (version 1.1.27). For
AP the staining intensity (score 1 = no, score 2 = low, score
3 = moderate, score 4 = high) was evaluated. For GLO1 the
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relative amount of positive tumor cells (score 1 = no
positive cell, score 2 ≤ 33%, 33% > score 3 ≤ 66%, score
4 > 66%) and the staining intensity (score 1 = no, score
2 = low, score 3 = moderate, score 4 = high) was evalu-
ated (Additional file 3: Table S3). Both scores were sig-
nificantly correlated (Pearson correlation coefficient
0.696, p < 0.005 and Spearman correlation coefficient
0.586, p < 0.005) and multiplied to calculate the final
immunoreactivity score (IRS, range 1–16). The cut-off
value for further analysis was: GLO1high > 8 and GLO1-
low ≤ 8. The intracellular staining of GLO1 was evalu-
ated as predominant nuclear (GLO1nuc) versus
cytoplasmic (GLO1cyt) (Additional file 4: Table S4).
Cell culture experiments
Human cell lines (FaDu and Cal27) were purchased
from ATCC (http://www.lgcstandards-atcc.org; catalog
numbers: HTB-43™ and CRL-2095™) and were main-
tained in http://www.sigmaaldrich.com (Sigma, Germany)
supplemented with 10% fetal bovine serum (Invitrogen,
Germany), 2 mM L-Glutamine (Invitrogen, Germany) and
50 μg/ml Penicillin-Streptomycin (Invitrogen, Germany)
in a humidified atmosphere of 6% CO2 at 37 °C. Authenti-
cation of both cell lines was confirmed by the Multiplex
Human Cell Line Authentication Test (Multiplexion,
Germany). For Western blot analysis 1 × 106 FaDu or
Cal27 cells were seeded on 96 mm TC plates and cultured
over night. Cells were treated with indicated concentra-
tions of MG and 24 h following administration cells were
harvested for protein lysates. MG was synthesized by acid
hydrolysis as described [22], and the concentration of the
stock solution was determined by derivatization with
aminoguanidine [23]. The cell permeable GLO1 inhibi-
tor, S-p-bromobenzylglutathione cyclopentyl diester
(BrBzGSHCp2) was prepared and characterized as de-
scribed [24, 25]. For colony formation assays 100 and
300 FaDu cells or 300 and 1000 Cal27 cells were seeded
per 6-well plate, respectively. Cells were treated with
the indicated concentration of MG or the GLO1 inhibi-
tor every second day. 10 days upon seeding cells were
PFA-fixed and the amount of colonies was determined
after crystal violet staining as described in [26]. The
survival fraction was computed according to [27].
Protein isolation and Western blot analysis
Whole cell protein lysate was extracted using RIPA
(Radioimmunoprecipitation assay) buffer [28] and prote-
ase and phosphatase inhibitor cocktails (Sigma-Aldrich).
20 μg of denatured protein were separated by
Sodiumdodecylsulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to polyvinyl difluoride
(PVDF) membranes (Millipore, Germany). After blocking
with 5% milk (Roth, Germany), membranes were incu-
bated with primary and horseradish peroxidase coupled-
secondary antibodies, which are listed in Supplementary
Table S2. Membranes were incubated in enhanced chemi-
luminiscence solution (Thermo Scientific, Germany) and
developed with an E.O.S. developer (Agfa, Germany).
Quantification of MG levels by HPLC
The concentrations of MG in supernatant of cultured cells
were determined by derivatization with 1,2-diamino-4,5-
dimethoxybenzene and HPLC of the quinoxaline adduct
by fluorescence detection as described elsewhere [22, 29].
Statistical analysis
Statistical analysis was conducted with the IBM SPSS Sta-
tistics software (version 21). Differences between sub-
groups were assessed using Chi square or Fisher’s exact
tests. The method of Kaplan–Meier was used to estimate
survival distributions and differences between groups were
determined by log-rank tests. Univariate and multivariate
Cox proportional hazard model was used to assess the as-
sociation between patient subgroups and progression-free
or disease-specific survival. In all statistical tests, a p-value
of 0.05 or below was considered as statistically significant.
Results
Detection of AP modification and correlation with GLO1
expression in primary oropharyngeal squamous cell
carcinoma
Tissue microarrays were analyzed by immunohistochem-
istry with an anti-AP antibody as a surrogate marker for
MG accumulation in tumor cells of primary OPSCC. In
parallel, GLO1 protein levels were analyzed by immuno-
histochemistry on serial sections of tissue microarrays.
Data on AP and GLO1 immunoreactivity were available
for tumor specimens of 134 patients, and revealed no
AP staining in 3.7% (n = 5), low staining pattern in
20.9% (n = 28), moderate staining pattern in 31.4%
(n = 42), and a high staining pattern in 44% (n = 59)
(Fig. 1A, C, E and G). A heterogeneous staining pattern
was also evident for GLO1 considering the staining in-
tensity as well as the relative amount of positive tumor
cells (Fig. 1B, D, F and H). It is worth noting that in
addition to the expected positive staining in the cyto-
plasm of tumor cells (Fig. 1F), we also detected a prom-
inent nuclear GLO1 staining in a substantial amount of
OPSCC samples (Fig. 1H). Comparison of the relative
GLO1 immunoreactivity score in subgroups of OPSCC
patients with no, low, moderate or high AP staining
demonstrated a significant positive correlation (Fig. 1I).
Impact of MG on GLO1 expression and viability of tumor
cell lines
The data presented so far suggested that induced GLO1
expression is a compensatory mechanism of OPSCC
tumor cells to counteract and survive the accumulation
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of MG. To further support this assumption FaDu and
Cal27, two well-established head and neck cancer cell
lines, were cultured in the presence of increasing
amounts of MG. In both cell lines, administration of ex-
ogenous MG increased GLO1 protein levels as deter-
mined by Western blot analysis (Fig. 2A). It is worth
noting that GLO1 levels were lower in Cal27 as com-
pared to FaDu cells under control conditions as well as
the presence of exogenous MG.
Next, the cytotoxic profile of MG treatment on tumor
cell viability was analyzed by a colony-forming assay. No
major difference between both cell lines was found at
lower MG concentrations (≤ 40 μM, Additional file 5: Fig.
S1). However, at higher MG concentrations FaDu cells
displayed an improved survival as compared to Cal27
cells, which was statistical significant at a MG con-
centration of 160 μM (p ≤ 0.049, Fig. 2B). These data
indicated a better tolerance of tumor cells with higher
basal or inducible GLO1 expression under conditions
of MG accumulation.
Impact of GLO1 inhibition on tumor cell survival
To assess the consequence of GLO1 inhibition on tumor
cell survival we cultured both cell lines in the presence
of the cell permeable inhibitor S-p-bromobenzylglu-
tathione cyclopentyl diester [3]. Quantification of MG
levels in cell culture supernatant after treatment with
the GLO1 inhibitor revealed a concentration dependent
increase in FaDu but not Cal27 cells (Additional 6: Fig.
S2). However, both cell lines showed a comparable de-
crease in the survival fraction with increasing amount of
the GLO1 inhibitor (Fig. 2C-D). These data strongly sug-
gested that the cytotoxic effect of GLO1 inhibition does
not exclusively rely on an accumulation of MG levels.
Prognostic value of the GLO1 staining pattern
To evaluate the clinical relevance of GLO1 staining pat-
terns in the cohort of OPSCC patients, subgroups with a
low (GLO1low, n = 67) or a high immunoreactivity score
(GLO1high, n = 89) were identified. Furthermore, we
considered a cytoplasmic (GLO1cyt, n = 94) or a
Fig. 1 Detection of AP modifications and GLO1 protein expression in tumor cells of OPSCC. Representative pictures of an immunohistochemical
staining with an anti-AP antibody (brown staining) demonstrate tumor sections with low (a), moderate (c) or high staining (e and g). Serial sec-
tions were analyzed with an anti-GLO1 antibody and revealed a heterogeneous staining pattern (brown signal) with low (b), moderate (d) and
high immunoreactivity scores (f and h), considering staining intensity and relative amount of positive tumor cells. GLO1 staining was detected ei-
ther in the cytoplasm (f) or the nucleus (h) of tumor cells. i Boxplot displays the median and 25% to 75% percentile of the GLO1 immunoreactiv-
ity score in subgroups of OPSCC patients (n = 134) with no, low, moderate or high AP staining. *p ≤ 0.05, **p ≤ 0.005 and ***p ≤ 0.0005.
Counterstaining was done with hematoxylin to visualize tissue architecture; white bar indicates 200 μm
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predominant nuclear staining (GLO1nuc, n = 43) in the
subgroup of OPSCC patients with a positive GLO1
staining. A GLO1high staining was significantly corre-
lated with shorter progression-free (PFS) and disease-
specific survival (DSS), while nuclear GLO1 staining re-
vealed a trend towards shorter PFS and was significantly
correlated with shorter DSS (Fig. 3A-D). These findings
strongly indicated that a nuclear GLO1 accumulation
in tumor cells with a high expression serves as a risk
factor for unfavorable prognosis of OPSCC patients.
This assumption was further assessed by a combina-
torial subgroup analysis taking into account both fea-
tures (GLO1high/nuc) in comparison to all other
staining patterns (GLO1others), and confirmed a highly
significant shorter PFS and DSS (Fig. 3E-F). Moreover,
a high and nuclear GLO1 staining was significantly
associated with a larger tumor size (Table 1), but not
with any other patient characteristic tested (e.g. gen-
der, age, TNM status, pathological grading, clinical
staging, alcohol and tobacco consumption or HPV
status). Next, multivariate Cox proportional hazard
model analysis confirmed that a GLO1high/nuc staining
pattern served as independent risk factors for un-
favorable PFS and DSS (Table 2), taking into consid-
eration relevant prognostic risk factors based on
univariate analysis (Additional 7: Table S5).
Finally we addressed the question, whether the prognos-
tic value of GLO1 staining patterns correlates with the
mode of treatment and conducted subgroup analysis by
univariate Cox regression analysis. While the prognostic
value of nuclear GLO1 staining was largely independent
of treatment with (n = 109) or without surgery (n = 46), a
high GLO1 immunoreactivity score was significantly
correlated with an unfavorable PFS after surgery (with or
without adjuvant radio- or radiochemotherapy, Additional
file 8: Fig. S3A). A similar trend was also found for DSS
(Additional file 9: Fig. S3B). In contrast, a high GLO1 im-
munoreactivity score was significantly correlated with a
poor clinical outcome in the absence of chemotherapy
(n = 108), which was not observed for patients with
chemotherapy (n = 47, Additional file 10: Fig. S4). All
GLO1 staining patterns (high or nuclear GLO1 staining
and their combination) were correlated with unfavorable
PFS and DSS after radiotherapy (n = 131, adjuvant and de-
finitive), but not for surgery only (n = 24, Additional Fig.
S5). However, it is worth noting that the amount of cases
without radiotherapy was limited in this retrospective
cohort.
Discussion
GLO1 is a central part of a ubiquitous detoxification sys-
tem in the glycolytic pathway of normal and tumor cells,
Fig. 2 Impact of MG and a GLO1 inhibitor on colony formation of tumor cells. Western blot analysis with whole cell lysate demonstrates higher
basal GLO1 expression in control treated (co) FaDu as compared to Cal27 cells and MG-induced up-regulation of GLO1 protein levels in both cell
lines (a). Detection of β-Actin served as control for quantity and quality of protein lysates. b The cytotoxic effect of MG on FaDu (black line) and Cal27
cells (dashed line) was assessed by a colony-forming assay and the graph indicates the mean value ±SD of the survival fraction at the indicated MG
concentration of three independent experiments. The impact of GLO1 inhibition (1 and 5 μM S-p-bromobenzylglutathione cyclopentyl diester) on the
viability of FaDu and Cal27 cells was assessed by a colony-forming assay (b) and the graph in (c) displays the mean value ±SD of the survival fraction
at the indicated concentration of the GLO1 inhibitor from three independent experiments
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and enables cell proliferation and survival under dicarbo-
nyl stress [4]. Accordingly, GLO1 overexpression was
found in several human malignancies [3, 7], and is also a
common feature in tumor tissue of primary OPSCC as
demonstrated by immunohistochemistry in this study.
High GLO1 expression was significantly correlated with
the presence of AP modifications and administration of
exogenous MG induced GLO1 protein levels in two
HNSCC cell lines. Induced GLO1 expression as an adap-
tive response to elevated MG levels was reported previ-
ously for triple negative breast cancer cell lines [30]. These
data support a compensatory induction of GLO1 expres-
sion as a common mechanism of tumor cells to counter-
act the cytotoxic effect of an MG accumulation, which
appears to be a critical step in the pathogenesis and malig-
nant progression of OPSCC. Accordingly, Cal27 with
lower basal and MG-induced GLO1 expression were more
sensitive in a colony-forming assay to the cytotoxic effect
at high MG concentrations, which is consistent with the
sensitization to exogenous MG of metastatic melanoma
and prostate cancer cell lines after silencing of GLO1 ex-
pression [14, 31].
Fig. 3 High expression and nuclear localization of GLO1 correlates with unfavorable survival. The prognostic value of high versus low GLO1 expression
(a-b) and its predominant cytoplasmic versus nuclear localization (c-d) was assessed for progression-free (PFS, left panel) and disease-specific survival
(DSS, right panel) in a Kaplan-Meier plot. The worst outcome was observed for OPSCC patients with a combined high and nuclear GLO1 staining as
compared to all other staining patterns (e-f). P values were calculated by a log-rank test
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Patients with a high GLO1 expression had a significantly
shorter progression-free and disease-specific survival, sug-
gesting a critical role of GLO1 activity not only in the ini-
tiation and maintenance of malignant tumor growth, but
also the invasive capacity and metastatic spread of OPSCC
tumor cells. Indeed, a significant correlation between
GLO1 overexpression and tumor cell invasion, lymph
node metastasis as well as reduced 5-year survival was
reported for gastric cancer [8]. Furthermore, a growing
body of experimental evidence indicates a potential role
for GLO1 in tumor cell motility and invasion, which was
demonstrated by ectopic GLO1 overexpression or gene si-
lencing in established tumor cell lines derived from gastric
cancer [8], cutaneous SCC [13], and prostate cancer [15].
In this context it is also worth noting that high GLO1 ex-
pression has been linked to the activation of distinct key
Table 1 Correlation between GLO1high/nuc staining and patient characteristics
GLO1high/nuc GLO1others
Features Category N % N % p value3
Age [years] < 58.25 18 64.3 63 49.2 0.148
≥ 58.25 10 35.7 65 50.8
Gender Male 20 71.4 96 75.0 0.695
Female 8 28.6 32 25.0
T status T1-T2 6 21.4 64 50.4 0.005
T3-T4 22 78.6 63 49.6
N status N0 6 21.4 25 19.7 0.835
N+ 22 78.6 102 80.3
M status M0 25 92.6 120 96.0 0.444
M+ 2 7.4 5 4.0
Pathological grading G1–2 14 66.7 62 56.4 0.381
G3 7 33.3 48 43.6
Clinical staging I-III 5 17.9 44 34.6 0.084
IV 23 82.1 83 65.4
Alcohol no/former 3 11.1 29 24.2 0.137
current 24 88.9 91 75.8
Tobacco no/former 3 11.1 29 23.8 0.147
current 24 88.9 93 76.2
HPV non-related1 24 88.9 83 75.5 0.130
related2 3 11.1 27 24.5
1 viral DNA-negative or DNA-positive but transcript-negative; 2 viral DNA- and transcript-positive according to [20]; 3 Chi-square test
Significant results (p <0.05) (including the HR, 95% CI) are marked in boldface
Table 2 Multivariate Cox regression models for progression-free and disease-specific survival
Progression-free survival Disease-specific survival
Risk factor HR 95% CI p-value HR 95% CI p-value
T status
T3–4 vs T1–21
1.282 0.749–2.197 0.365 1.230 0.667–2.268 0.508
N status
N+ vs N01
1.655 0.804–3.409 0.171 2.435 1.023–5.796 0.044
Clinical staging
IV vs I-III1
1.516 0.771–2.983 0.228 1.702 0.778–3.722 0.183
Tobacco
current vs never/former1
2.315 1.174–4.564 0.015 1.732 0.876–3.426 0.114
HPV status2
Non-related vs related1
0.412 0.200–0.849 0.016 0.356 0.157–0.805 0.013
Subgroup
GLO1high/nuc vs GLO1others, 1
1.784 1.054–3.018 0.031 1.791 1.037–3.094 0.037
HR Hazard ratio, CI confidence interval, 1reference group, 2related = viral DNA+RNA+, non-related = viral DNA+RNA− or viral DNA− according to [20]
Significant results (p <0.05) (including the HR, 95% CI) are marked in boldface
Kreycy et al. BMC Cancer  (2017) 17:382 Page 7 of 9
regulators in oncogenic signaling, such as NF-κB, AP1
and PI3K-AKT, which might contribute to tumor cell pro-
liferation and survival, but also accelerated tumor cell mo-
tility, metastasis and treatment resistance [7].
In a substantial amount of OPSCCs with GLO1 ex-
pression, we detected a predominant nuclear staining in
tumor cells. Nuclear GLO1 staining was already reported
for human cutaneous basal cell carcinoma [13] and pros-
tate cancer [15], and nuclear GLO1 translocation was
shown in a cell culture model of murine fibrosarcoma
[32]. But for the first time, we demonstrate that nuclear
GLO1 translocation has a clinical impact as it is signifi-
cantly correlated with shorter disease-specific survival.
Furthermore, the combination of high and nuclear
GLO1 staining serves as independent risk factor for an
unfavorable outcome of OPSCC patients. So far, the
mode of regulation and causal role of nuclear GLO1 in
malignant progression and treatment failure remains
largely elusive and will be a major challenge for future
studies. It has been speculated that one consequence of
DNA damaging therapy is a dramatic increase in MG
formation due to active processes of DNA repair [3]. As
a consequence DNA and nuclear proteins become modi-
fied, which might potentiate the cytotoxic effect of anti-
tumor treatment. The presence of nuclear GLO1 might
serve as a potent defense mechanism to protect key reg-
ulators of DNA repair and tumor cell survival in the nu-
cleus from inactivation by MG-induced modification.
Conclusions
In summary, the presented data support a critical role of
GLO1 in the malignant progression and clinical outcome
of OPSCC patients. Detection of a high and nuclear
GLO1 staining pattern could be implemented in future
clinical studies to identify OPSCC patients with a high risk
for treatment failure, which might benefit from specific
targeting of accelerated GLO1 expression and activity.
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